EUVIMEDEUVIMED entdecken
Crossref

Effects of silymarin supplementation in patients with chronic hepatitis C receiving PEG-IFN + ribavirin antiviral therapy. A placebo-controlled double blind study

Alajos Pár, Erzsébet Rőth, Attila Miseta, Géza Hegedűs, Gabriella Pár, Béla Hunyady, Áron Vincze

Clinical and Experimental Medical Journal · 2009

DOI: 10.1556/cemed.3.2009.28517 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical and Experimental Medical Journal, 2009. Verfasst von Alajos Pár und 6 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 24 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives Since oxidative stress may play a pathogenetic role in chronic hepatitis C and the sustained virological response to antiviral therapy is limited in HCV1 genotype infection, a double blind study was performed in HCV1 patients receiving peginterferon + ribavirin treatment, in order to assess the efficacy of supplementation with an antioxidant flavonoid, silymarin. Patients and Methods 32 naive HCV1-positive patients with biopsy-proven chronic hepatitis C, to be treated with peginterferon + ribavirin, have been randomised as follows: Group A: 16 patients received antiviral therapy for 6 to 12 months plus placebo for the first 3 months; Group B: 16 patients were treated with peginterferon + ribavirin for 6 to 12 months plus they received 166 mg oral silymarin twice a day for 3 months. Serum alanine aminotransferase and HCV RNA levels, as well as parameters of oxidative stress such as plasma or RBC haemolysate malondialdehyde, superoxide dismutase, glutathione peroxidase, catalase and myel...

Zitieren

APA

Pár, A., Rőth, E., Miseta, A., Hegedűs, G., Pár, G., Hunyady, B., & Vincze, Á. (2009). Effects of silymarin supplementation in patients with chronic hepatitis C receiving PEG-IFN + ribavirin antiviral therapy. A placebo-controlled double blind study. Clinical and Experimental Medical Journal. https://doi.org/10.1556/cemed.3.2009.28517

Vancouver

Pár A, Rőth E, Miseta A, Hegedűs G, Pár G, Hunyady B, et al. Effects of silymarin supplementation in patients with chronic hepatitis C receiving PEG-IFN + ribavirin antiviral therapy. A placebo-controlled double blind study. Clinical and Experimental Medical Journal. 2009. doi:10.1556/cemed.3.2009.28517

BibTeX
@article{Pr2009,
  author = {Pár, Alajos and Rőth, Erzsébet and Miseta, Attila and Hegedűs, Géza and Pár, Gabriella and Hunyady, Béla and Vincze, Áron},
  title = {Effects of silymarin supplementation in patients with chronic hepatitis C receiving PEG-IFN + ribavirin antiviral therapy. A placebo-controlled double blind study},
  journal = {Clinical and Experimental Medical Journal},
  year = {2009},
  doi = {10.1556/cemed.3.2009.28517}
}
Kostenlos starten →